2-(2-oxoindoline-3-ylidene)methyl-5-(2hydroxy-3-morpholin-4-yl -propyl)-6,7-dihydro -1Hpyrrol[3,2-c]pyridine-4(5H)-one compounds and use as protein kinase inhibitors

Details for Australian Patent Application No. 2008288615 (hide)

Owner Jiangsu Hengrui Medicine Co., Ltd. Shanghai Hengrui Pharmaceutical Co., Ltd.

Inventors Su, Yidong; Tang, Peng Cho; Zhao, Fuqiang; Yang, Jialiang

Agent Davies Collison Cave

Pub. Number AU-A-2008288615

PCT Pub. Number WO2009/024016

Priority 200710141874.9 15.08.07 CN

Filing date 29 July 2008

Wipo publication date 26 February 2009

International Classifications

C07D 417/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

A61K 31/437 (2006.01)

A61P 33/00 (2006.01) Antiparasitic agents

C07D 209/04 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 209/30 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

Event Publications

1 April 2010 PCT application entered the National Phase

  PCT publication WO2009/024016 Priority application(s): WO2009/024016

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008288631-Equipment of continuing pneumatic electric impulse

2008288611-A method for improving the yield(s) of ethylene and/or propylene during the conversion process